NDA 022387 · United Therap
Tyvaso
Treprostinil · Inhalation · Prostacycline Vasodilator
OrphanLast checked: Nov 20, 2026Latest source record: Apr 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Jul 30, 2009
Approved uses
4
Original approval plus efficacy supplements
Registered trials
129
42 Phase 3, 15 recruiting
FAERS reports
44,108
26,272 serious, 5,847 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 14, 2026.
Tyvaso is a prostacyclin mimetic indicated for the treatment of: Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). ( 1.1 ) Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%). ( 1.2 ) 1.1 Pulmonary Arterial Hypertension Tyvaso is indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities. While there are long-term data on use of treprostinil by other routes of administration, nearly all controlled clinical experience with inhaled treprostinil has been on a background of bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase type 5 inhibitor). The controlled clinical experience was limited to 12 weeks in duration [see Clinical Studies (14) ] . 1.2 Pulmonary Hypertension Associated with ILD Tyvaso is indicated for the treatment of pulmonary hypertension associated...
Mechanism: Treprostinil is a prostacyclin analogue. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 31, 2021 Supplement 17 · Efficacy OrphanLabelLetterReview
- Oct 19, 2017 Supplement 15 · Efficacy OrphanLetterLabel
- May 20, 2014 Supplement 9 · Efficacy OrphanLabelLetter
- Jul 30, 2009 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLabelOtherLetter
1 products under this application
- TYVASO · TREPROSTINIL 0.6MG/ML · SOLUTION, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Treprostinil" as an intervention, any sponsor and status, largest first.
- Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung DiseasePivotal-lookingEnrolling by invitation
United TherapeuticsIndustry
NCT04905693 · 1,850 participants (planned) · Start Sep 6, 2022 · Primary completion Dec 2029
Drug: Inhaled Treprostinil · For: Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease; Progressive Pulmonary Fibrosis
Sites: Birmingham, Alabama; Franklin, Arizona; Phoenix, Arizona · 192 sites in all
- An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial HypertensionPivotal-lookingCompleted
United TherapeuticsIndustry
NCT01027949 · 894 participants · Start Jan 16, 2007 · Primary completion Feb 12, 2020
Drug: Oral Treprostinil · For: Pulmonary Arterial Hypertension
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 134 sites in all
- A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)Pivotal-lookingRecruiting
Insmed IncorporatedIndustry
NCT07805785 · 800 participants (planned) · Start Dec 1, 2026 · Primary completion Aug 31, 2030
Drug: Treprostinil Palmitil Inhalation Powder; Placebo · For: Progressive Pulmonary Fibrosis; Interstitial Lung Disease
Sites: DuBois, Pennsylvania
- Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)Pivotal-lookingRecruiting
United TherapeuticsIndustry
NCT05943535 · 698 participants (planned) · Start Oct 30, 2023 · Primary completion Nov 2027
Drug: Placebo; Inhaled Treprostinil · For: Progressive Pulmonary Fibrosis; Interstitial Lung Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 165 sites in all
- Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral MonotherapyPivotal-lookingCompleted
United TherapeuticsIndustry
NCT01560624 · 690 participants · Start Jun 26, 2012 · Primary completion Jun 24, 2018
Drug: Treprostinil Diolamine; Placebo · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; Tucson, Arizona; Fresno, California · 155 sites in all
- Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisPivotal-lookingCompleted
United TherapeuticsIndustry
NCT04708782 · 598 participants · Start Jun 1, 2021 · Primary completion Feb 2, 2026
Drug: Placebo; Inhaled Treprostinil · For: Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 98 sites in all
- Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisPivotal-lookingCompleted
United TherapeuticsIndustry
NCT05255991 · 597 participants · Start Sep 12, 2022 · Primary completion Jun 30, 2025
Drug: Placebo; Inhaled Treprostinil · For: Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease
Sites: Ciudad Autonoma de Buenos Aires, Argentina; Mar del Plata, Argentina; Córdoba, Argentina · 108 sites in all
- An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial HypertensionPivotal-lookingCompleted
United TherapeuticsIndustry
NCT01560637 · 471 participants · Start Sep 11, 2013 · Primary completion Aug 12, 2021
Drug: UT-15C (treprostinil diolamine) · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; Tucson, Arizona; Fresno, California · 153 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea8,544
- cough6,585
- headache6,381
- diarrhoea4,111
- dizziness3,983
- nausea3,945
- fatigue3,824
- death3,423
- off label use3,291
- pneumonia2,360
- hypotension2,306
- oxygen saturation decreased2,113
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 9 |
| 2010 | 253 |
| 2011 | 805 |
| 2012 | 911 |
| 2013 | 811 |
| 2014 | 4,869 |
| 2015 | 4,317 |
| 2016 | 3,283 |
| 2017 | 2,627 |
| 2018 | 2,678 |
| 2019 | 2,668 |
| 2020 | 2,388 |
| 2021 | 2,920 |
| 2022 | 3,965 |
| 2023 | 3,406 |
| 2024 | 3,084 |
| 2025 | 3,086 |
| 2026 | 2,021 |
Recalls
1 FDA enforcement reports for this application.
Aug 14, 2018 · Class III · Terminated
Defective Delivery System: Water ingress through the lower water cup sensor of the device.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Tyvaso* (Treprostinil*) · HCPCS J7686
2024 spending
$183M
Beneficiaries
1,226
8,988 claims
Per beneficiary
$149,284
2024 ASP limit $743.92 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $217,247,290 |
| 2021 | $253,875,006 |
| 2022 | $256,380,566 |
| 2023 | $205,576,762 |
| 2024 | $183,021,609 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.
Nathan SD, Smith P, Deng C, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Multicenter Study
- Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.
Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. · N Engl J Med 2021 · Multicenter Study, Randomized Controlled Trial
- Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.
Nathan SD, Smith P, Deng C, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results.
Nathan SD, Argula R, Trivieri MG, et al. · Eur Respir J 2024 · Randomized Controlled Trial, Multicenter Study
- Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study.
Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. · Eur Respir J 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.
Nathan SD, Waxman A, Rajagopal S, et al. · Lancet Respir Med 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: United Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.